Valneva SE

(NASDAQ: VALN)

Johnson Fistel Investigates Valneva Following FDA Suspension

Johnson Fistel, PLLP announces that it is investigating potential claims on behalf of investors of Valneva SE (NASDAQ: VALN) regarding possible violations of federal securities laws. Investors who purchased Valneva securities may be eligible to recover losses stemming from alleged misrepresentations and omissions made by the company and its executives.

This field is for validation purposes and should be left unchanged.

If you suffered a loss on your investment and would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. The information provided will be held in strict confidence unless and until you authorize us to disclose it.

Name(Required)

First Last

Email(Required)

Phone(Required)

Estimated Losses(Required)

Where did you see our press release?(Required)

If you selected 'Other' above, please specify below:(Required)

Would you like to receive future case and securities updates from Johnson Fistel, PLLP via email?(Required)

Yes

Would you like to receive information about Johnson Fistel, PLLP's free portfolio monitoring service?(Required)

Yes

By checking the box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Johnson Fistel, PLLP, and that submission to or receipt of information from the firm or one of its attorneys via this form, website, email, or telephone does not create an attorney-client relationship.(Required)

I Agree

For more information, contact James Baker at (619) 814-4471, jimb@johnsonfistel.com or fjohnson@johnsonfistel.com.

Background: On August 25, 2025 Valneva acknowledged that the FDA has, with immediate effect, suspended the license for its chikungunya vaccine Ixchiq following four reports of serious adverse events consistent with the disease, thereby mandating that Valneva cease all shipping and sale of the vaccine within the United States.

Valneva SE

Johnson Fistel Investigates Valneva Following FDA Suspension

California

New York

Georgia

Colorado

Idaho